Article ; Online: IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
NEJM evidence
2022 Volume 2, Issue 1, Page(s) EVIDoa2200167
Abstract: IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 ... ...
Abstract | IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 superagonist, plus BCG. Primary end points were CR at 3 or 6 months for patients with CIS disease and DFS rate at 12 months for those with high-grade Ta/T1 disease. CR rate was 71% (58 of 82 patients), and the DFS rate was 55.4%. |
---|---|
MeSH term(s) | Humans ; BCG Vaccine ; Non-Muscle Invasive Bladder Neoplasms ; Interleukin-15 ; Urinary Bladder Neoplasms/therapy |
Chemical Substances | BCG Vaccine ; Interleukin-15 |
Language | English |
Publishing date | 2022-11-10 |
Publishing country | United States |
Document type | Journal Article |
ISSN | 2766-5526 |
ISSN (online) | 2766-5526 |
DOI | 10.1056/EVIDoa2200167 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.